Companies › Checkpoint Therapeutics
1 active drug program in 2 registered trials: 1 Phase 1, 1 Phase 4; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cosibelimab (CK-301) Programmed cell death 1 ligand 1 inhibitor | CD274 | Phase 1 | Lung Neoplasms; Cutaneous Squamous Cell Carcinoma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03212404 | Cosibelimab (CK-301) | Phase 1 | Lung Neoplasms | Oncology | Nov 2021 |
| NCT07426484 | Cosibelimab (CK-301) | Phase 4 | Cutaneous Squamous Cell Carcinoma | Oncology | Dec 2030 |
AstraZeneca Pfizer IO Biotech ImmuneOncia Therapeutics Akeso Roche Biotheus Suzhou Suncadia Biopharmaceuticals Shine-On Biomedical 3D Medicines (Sichuan)
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.